This research led by Justin Lathia, PhD, examines why glioblastoma (GBM) outcomes differ between men and women by focusing on the immune system’s role in GBM. The work centers on microglia—immune cells in the brain that can either help fight tumors or, in some cases, support their growth.

Learn More

MD Anderson Cancer Center is developing first‑of‑its‑kind RNA‑targeting therapies for glioblastoma (GBM). By focusing on the powerful role of non‑coding RNAs, MD Anderson researchers are exploring a new therapeutic strategy that shows remarkable promise in patient‑derived tumor models and could pave the way for a new class of GBM treatments.

Learn More

Project MAP-GLIOMA utilises spatial biology to examine tumour samples in their natural state, preserving important characteristics often lost during traditional analysis methods.

Learn More

Supported by a $50,000 Glioblastoma Research Organization grant, Project Kenny pioneers the first fully implantable, rechargeable Tumor Treating Fields (TTF) device aimed at delivering 24/7 therapy without external hardware.

Learn More

The Brain Tumor Funders' Collaborative (BTFC) announced a request for proposals for two-year, $500,000 research grants for multi-institutional, multi-disciplinary research projects focusing on liquid biopsy for primary brain tumors.

Learn More

Project Build On, a research initiative underway at The University of Texas MD Anderson Cancer Center, explores strategic ways to target metabolic weaknesses of glioblastoma. Through innovative drug combinations, researchers aim to block key pathways that fuel cancer growth, offering new hope for patients with this aggressive disease.

Learn More

Marking the GBMRO'S first funded research project of 2025, Project Rocket, formally known as Characterizing Glioblastoma Progression, Pseudoprogression, and Radiation Necrosis with Bedside Ultrasound Using Sonolucent Cranial Implants, led by Dr. Randy S. D’Amico, aims to identify key ultrasound markers that reveal whether the tumor is growing, healing, or experiencing other changes.

Learn More

The Glioblastoma Research Organization (GBMRO) announces its largest donation to date, $80,000, to fund Project DeLaRosa in partnership with Children's National Hospital.

learn more

Project Every Day Counts was launched with a $50,000 donation in collaboration with Gray for Glioblastoma Society to Children’s Hospital Los Angeles. The project honors Josh Wexler and the Wexler Family and their dedication to furthering GBM research.

learn more

Project Garcia marks GBMRO’s fourth fully funded Glioblastoma research project and the first in collaboration with Sylvester Comprehensive Cancer Center in Miami, Florida. The project includes novel research that uniquely applies a multiparametric intraoperative strategy to guide tumor resection and identify infiltrating tumor cells responsible for tumor recurrence.

learn more

The median age for diagnosis of Glioblastoma is 65, with patient prognosis known to decline with increased age. Christopher Hine, Ph.D., a researcher in the Department of Cardiovascular and Metabolic Sciences at Cleveland Clinic's Lerner Research Institute, has a theory that could explain why.

learn more

The Glioblastoma Research Organization's Project Rush is in collaboration with Lenox Hill Hospital’s Department of Neurosurgery’s Brain Tumor Center in New York City. Project Rush was inspired by the passing of Neil Peart a Canadian-American musician, best known as the drummer and lyricist of the rock band, Rush.

learn more

Funded by the Glioblastoma Research Organization, the laboratory of Dr. Steven Millward at the University of Texas MD Anderson Cancer Center has launched The Lee Project, which focuses on the directed evolution of vectors for treating GBM.

learn more

Brain tumors are the leading cause of cancer-related death in children. Of all the pediatric brain tumors, high-grade gliomas (HGG) remain the greatest challenge, with few treatment options available and a five-year survival rate of only 10-30 percent. A potential alternative to conventional treatments is to utilize a patient’s own immune system to attack tumor cells—immunotherapy.

learn more

This research led by Justin Lathia, PhD, examines why glioblastoma (GBM) outcomes differ between men and women by focusing on the immune system’s role in GBM. The work centers on microglia—immune cells in the brain that can either help fight tumors or, in some cases, support their growth.

Learn More

MD Anderson Cancer Center is developing first‑of‑its‑kind RNA‑targeting therapies for glioblastoma (GBM). By focusing on the powerful role of non‑coding RNAs, MD Anderson researchers are exploring a new therapeutic strategy that shows remarkable promise in patient‑derived tumor models and could pave the way for a new class of GBM treatments.

Learn More

Project MAP-GLIOMA utilises spatial biology to examine tumour samples in their natural state, preserving important characteristics often lost during traditional analysis methods.

Learn More

Supported by a $50,000 Glioblastoma Research Organization grant, Project Kenny pioneers the first fully implantable, rechargeable Tumor Treating Fields (TTF) device aimed at delivering 24/7 therapy without external hardware.

Learn More

The Brain Tumor Funders' Collaborative (BTFC) announced a request for proposals for two-year, $500,000 research grants for multi-institutional, multi-disciplinary research projects focusing on liquid biopsy for primary brain tumors.

Learn More

Project Build On, a research initiative underway at The University of Texas MD Anderson Cancer Center, explores strategic ways to target metabolic weaknesses of glioblastoma. Through innovative drug combinations, researchers aim to block key pathways that fuel cancer growth, offering new hope for patients with this aggressive disease.

Learn More

Marking the GBMRO'S first funded research project of 2025, Project Rocket, formally known as Characterizing Glioblastoma Progression, Pseudoprogression, and Radiation Necrosis with Bedside Ultrasound Using Sonolucent Cranial Implants, led by Dr. Randy S. D’Amico, aims to identify key ultrasound markers that reveal whether the tumor is growing, healing, or experiencing other changes.

Learn More

The Glioblastoma Research Organization (GBMRO) announces its largest donation to date, $80,000, to fund Project DeLaRosa in partnership with Children's National Hospital.

learn more

Project Every Day Counts was launched with a $50,000 donation in collaboration with Gray for Glioblastoma Society to Children’s Hospital Los Angeles. The project honors Josh Wexler and the Wexler Family and their dedication to furthering GBM research.

learn more

Project Garcia marks GBMRO’s fourth fully funded Glioblastoma research project and the first in collaboration with Sylvester Comprehensive Cancer Center in Miami, Florida. The project includes novel research that uniquely applies a multiparametric intraoperative strategy to guide tumor resection and identify infiltrating tumor cells responsible for tumor recurrence.

learn more

The median age for diagnosis of Glioblastoma is 65, with patient prognosis known to decline with increased age. Christopher Hine, Ph.D., a researcher in the Department of Cardiovascular and Metabolic Sciences at Cleveland Clinic's Lerner Research Institute, has a theory that could explain why.

learn more

The Glioblastoma Research Organization's Project Rush is in collaboration with Lenox Hill Hospital’s Department of Neurosurgery’s Brain Tumor Center in New York City. Project Rush was inspired by the passing of Neil Peart a Canadian-American musician, best known as the drummer and lyricist of the rock band, Rush.

learn more

Funded by the Glioblastoma Research Organization, the laboratory of Dr. Steven Millward at the University of Texas MD Anderson Cancer Center has launched The Lee Project, which focuses on the directed evolution of vectors for treating GBM.

learn more

Brain tumors are the leading cause of cancer-related death in children. Of all the pediatric brain tumors, high-grade gliomas (HGG) remain the greatest challenge, with few treatment options available and a five-year survival rate of only 10-30 percent. A potential alternative to conventional treatments is to utilize a patient’s own immune system to attack tumor cells—immunotherapy.

learn more